Market LIVE
Published markets; coverage varies by country
Product profile · United States

CALCIUM GLUCONATE IN SODIUM CHLORIDE

 ·  Patent Litigation & Settlement History ↓

IngredientCALCIUM GLUCONATE
Application typeNDA
Application208418
Product005
Dosage formSOLUTION
RouteINTRAVENOUS
Strength2GM/100ML (20MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval date2021-06-17
Marketing statusDiscontinued
Status event—
ApplicantFRESENIUS KABI USA
Product source

Current GenericRadar decision

Year2023
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFIRST_FINAL_ANDA
Anchor date2023-09-05
Patent anchor—
Exclusivity anchor—
Protection date2037-07-25
First Final ANDA2023-09-05
Status event2023-09-05

First Final ANDA 217174/002 approved 2023-09-05; direct RLD NDA208418 strength match. Product DISCN is retained separately.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
101306462037-07-25DP ————
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
217174 / 002FINAL_APPROVAL · FINAL_APPROVED2023-09-05—AMNEAL EU LTDNEXACT_PRODUCT · EXACT_PRODUCT_VERIFIEDSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 1 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
217174 / 002AMNEAL EU LTDFINAL_APPROVAL · FINAL_APPROVED2023-09-05 EXACT_PRODUCT · EXACT_PRODUCT_VERIFIEDSource—
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.